Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.16 – $5.00
59% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $789.3K | $695.0K | $1.2M | $217.0K | $1.1M | $718.6K | $3.0M | $5.9M |
| Cost of revenue | $3.8M | $4.4M | $9.4M | $91.9K | $773.7K | $25.0M | $236.7K | $464.4K |
| Gross profit | −$3.0M | −$3.7M | −$8.1M | $125.1K | $280.6K | −$24.3M | $2.8M | $5.4M |
| Gross margin | -382.0% | -536.3% | -660.0% | 57.7% | 26.6% | -3378.6% | 92.2% | 92.1% |
| R&D | $0 | $2.3M | $3.5M | $2.4M | $3.3M | $7.6M | $694.5K | $2.5M |
| Operating income | −$5.2M | −$7.0M | −$16.0M | −$13.7M | −$22.2M | −$30.7M | −$46.6M | −$29.2M |
| EBITDA | −$5.0M | −$6.7M | −$14.2M | −$18.0M | −$35.3M | −$43.8M | −$31.9M | −$46.0M |
| Net income | −$3.9M | −$6.5M | −$22.0M | −$21.4M | −$24.6M | −$31.5M | −$36.0M | −$30.1M |
| Net margin | -498.8% | -934.0% | -1783.0% | -9872.2% | -2332.6% | -4378.0% | -1179.8% | -513.7% |
| EPS (diluted) | -0.03 | -0.04 | -0.08 | -0.08 | -0.08 | -0.10 | -0.10 | -0.14 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $8M | $-0.17 | $-0.25–$-0.12 | 1 |
| 2027 | $22M | $-0.06 | $-0.09–$-0.04 | 1 |
| 2028 | $56M | $-0.03 | $-0.04–$-0.02 | 1 |
| 2029 | $90M | $0.00 | $0.00–$0.00 | 1 |
Forward consensus · source: Financial Modeling Prep
4DMEDICAL LTD
No one on the platform currently holds FDMDF.
No tracked institution reports a position in FDMDF as of their last filing.
No one on the platform has traded FDMDF yet.
| +0.00% |
| $334M |
| — |
| FOGCFAvisa Diagnostics Inc. | $0.00 | +0.00% | $97176 | — |
| GSGTFGenSight Biologics S.A. | $0.09 | +0.00% | $15M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 366.8× sales vs its 118.7× historical median P/S.
Fair value ≈ $0.97 · price $3.00 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.